Literature DB >> 11476561

Optimal management of endometrial hyperplasia.

D E Marsden1, N F Hacker.   

Abstract

The optimal management of endometrial hyperplasia is the subject of considerable debate. In this chapter the development of our current classification of endometrial hyperplasias is outlined in some detail in order to give an understanding of the complexity of the problem of determining the malignant potential of the hyperplasia which is the central issue in determining optimal treatment. While hysterectomy is still the definitive treatment for older women with hyperplasia, conservative therapy is perfectly acceptable in a defined group of younger women who are closely monitored. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11476561     DOI: 10.1053/beog.2000.0184

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  10 in total

1.  Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.

Authors:  Kristen Upson; Kimberly H Allison; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Elizabeth M Swisher; Jennifer A Doherty; Rochelle L Garcia
Journal:  Am J Obstet Gynecol       Date:  2012-05-16       Impact factor: 8.661

2.  Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development.

Authors:  Omar Habeeb; Lee Goodglick; Robert A Soslow; Rajiv G Rao; Lynn K Gordon; Osvaldo Schirripa; Steve Horvath; Jonathan Braun; David B Seligson; Madhuri Wadehra
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

3.  The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women.

Authors:  Seo Yeong Lee; Mi Kyoung Kim; Hyun Park; Bo Sung Yoon; Seok Ju Seong; Jin Hee Kang; Hye Sun Jun; Chong Taik Park
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

Review 4.  Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.

Authors:  Mi-La Kim; Seok Ju Seong
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

5.  Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

Authors:  James V Lacey; Mark E Sherman; Brenda B Rush; Brigitte M Ronnett; Olga B Ioffe; Máire A Duggan; Andrew G Glass; Douglas A Richesson; Nilanjan Chatterjee; Bryan Langholz
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

6.  Progestin therapy of complex endometrial hyperplasia with and without atypia.

Authors:  Susan D Reed; Linda F Voigt; Katherine M Newton; Rochelle H Garcia; H Kimberly Allison; Meira Epplein; Diana Jordan; Elizabeth Swisher; Noel S Weiss
Journal:  Obstet Gynecol       Date:  2009-03       Impact factor: 7.661

7.  LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial.

Authors:  Hatem Abu Hashim; Abdelhady Zayed; Essam Ghayaty; Mohamed El Rakhawy
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

8.  Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.

Authors:  Umberto Leone Roberti Maggiore; Fabio Martinelli; Giulia Dondi; Giorgio Bogani; Valentina Chiappa; Maria Teresa Evangelista; Viola Liberale; Antonino Ditto; Simone Ferrero; Francesco Raspagliesi
Journal:  J Gynecol Oncol       Date:  2019-02-26       Impact factor: 4.401

9.  Risk factors of progression to endometrial cancer in women with endometrial hyperplasia: A retrospective cohort study.

Authors:  Jin Young Jeong; Sung Ook Hwang; Banghyun Lee; Kidong Kim; Yong Beom Kim; Sung Hye Park; Hwa Yeon Choi
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

10.  Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan.

Authors:  J V Lacey; O B Ioffe; B M Ronnett; B B Rush; D A Richesson; N Chatterjee; B Langholz; A G Glass; M E Sherman
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.